secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001104659-25-028776
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics Q4 net loss $10.9M; SERENITY Phase 3 trial 63% enrolled; cash ~$35M
--------------------------------------------------------------------------------

- Net loss $10.9M in Q4 2024 vs $22.3M Q4 2023; full-year net loss $59.6M vs $179.1M.
- IGALMI net revenue $366K in Q4 ($376K Q4 2023); full-year $2.3M vs $1.4M in 2023.
- SERENITY At-Home Phase 3 trial enrollment at 63% (127/200 patients); topline data expected H2 2025.
- Closed $14M equity financing, strengthening cash to ~$35M as of March 4, 2025 (from $29.9M Dec 31, 2024).
- Cash used in operating activities $72M in 2024, down from $155M in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925028776/0001104659-25-028776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925028776/tm2510663d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-028776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer